Actemra (Tocilizumab (Intravenous))

Name: Actemra (Tocilizumab (Intravenous))

If OVERDOSE is suspected

If you think there has been an overdose, call your poison control center or get medical care right away. Be ready to tell or show what was taken, how much, and when it happened.

How do I store and/or throw out Actemra?

  • If you need to store this medicine at home, talk with your doctor, nurse, or pharmacist about how to store it.

Consumer Information Use and Disclaimer

  • If your symptoms or health problems do not get better or if they become worse, call your doctor.
  • Do not share your drugs with others and do not take anyone else's drugs.
  • Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.
  • Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.
  • Keep all drugs in a safe place. Keep all drugs out of the reach of children and pets.
  • Check with your pharmacist about how to throw out unused drugs.
  • This medicine comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time Actemra is refilled. If you have any questions about this medicine, please talk with the doctor, pharmacist, or other health care provider.
  • If you think there has been an overdose, call your poison control center or get medical care right away. Be ready to tell or show what was taken, how much, and when it happened.

This information should not be used to decide whether or not to take Actemra or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to Actemra. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this medicine.

Review Date: October 4, 2017

Usual Adult Dose for Giant Cell Arteritis

162 mg subcutaneously once a week in combination with a tapering course of glucocorticoids
Dose adjustment: 162 mg subcutaneously every other week in combination with a tapering course of glucocorticoids may be appropriate based on clinical considerations

Comments:
-This drug may be used alone following discontinuation of glucocorticoids.
-Interruption of dosing may be needed for management of dose-related laboratory abnormalities including elevated liver enzymes, neutropenia, and thrombocytopenia.
-This drug should not be initiated in patients with an absolute neutrophil count (ANC) below 2000 per mm3, platelet count below 100,000 per mm3, or who have ALT or AST above 1.5 times the upper limit of normal (ULN).
-IV administration is not approved for GCA.

Use: For giant cell arteritis (GCA)

Dialysis

Data not available

Other Comments

Administration advice:
Patients should be closely monitored during the infusion for signs and symptoms of a hypersensitivity reaction. Appropriately trained personnel, equipment, treatments, and protocols should be in place to manage an acute anaphylactic reaction.

Storage requirements:
Consult the manufacturer product information.

Reconstitution/preparation techniques:
Consult the manufacturer product information.

IV compatibility:
Consult the manufacturer product information.

(web3)